Back

Cytrellis enters South Korea with ellacor as market targets $1.1 billion by 2029

Verifying
  • Cytrellis agreed with KoreAx to commercialize ellacor in South Korea.
  • South Korea’s medical aesthetics market was valued at $572 million in 2023.
  • The launch follows Cytrellis’ earlier 2026 expansion into Australia.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.